Organogenesis Joins Russell 2000®, Russell 3000® and Russell Microcap® Indexes
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
“We are pleased to join these three Russell indexes,” said
FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in either the large-cap Russell 1000® Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes.
For more information on the Russell indexes and the Russell indexes reconstitution, please visit the “Russell Reconstitution” section on the FTSE Russell website.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as “will,” “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” “extend,” “continue” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward looking statements. These factors include the fact that rapid technological change could cause our products to become obsolete and if we do not enhance our product offerings through our research and development efforts, we may be unable to effectively compete; that to be commercially successful we must convince physicians that our products are safe and effective alternatives to existing treatments and that our products should be used in their procedures; and other risks and uncertainties described in the Company’s filings with the
Press and Media Inquiries:Angelyn Lowe alowe@organo.com 781-774-9364 Investor Inquiries:Westwicke Partners Mike Piccinino , CFA OrganoIR@westwicke.com 443-213-0500
Source: Organogenesis Holdings Inc.